Oxford, UK – 13 March 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, today announces its preliminary results for the twelve months ended 31 December 2014. Read More
Results date: – 13 March 2015: Oxford, UK – 6 March 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and… Read More
Oxford, UK – 5 March 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and cell therapy company, announces that Tim Watts, Chief Financial Officer, will present a company overview on 9 March 2015… Read More
London, UK – 3 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that John Dawson, Chief Executive Officer, and Tim Watts, Chief Financial Officer, will participate in… Read More
Oxford, UK – 23 February 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and cell therapy company, today welcomed the Rt Hon Danny Alexander, Chief Secretary to the Treasury, to its laboratories on the Oxford… Read More
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present… Read More
Oxford, UK – 3 November 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, today publishes its interim management statement for the period from 1 July to 31 October 2014. Read More
Oxford, UK – 13 October 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory facilities in… Read More
Oxford, UK – 10 October 2014: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy company, announces today that it has signed further contracts with Novartis which build on the collaboration with… Read More
Oxford, UK – 28 August 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a world-leading gene and cell therapy company, today announces its unaudited interim results for the six months ended 30 June 2014. Read More
— Dr Paul Blake to take Executive Role as Chief Development Officer — Oxford, UK – 15 August 2014: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica”… Read More
Oxford, UK – 23 June 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray’s GenomeRx Symposium on Monday, June 23, 2014 at The Yale… Read More